Patients with CNS metastases who are neurologically unstable or requiring increasing doses of steroids to control their CNS disease

patients with known hypersensitivity to somatostatin analogs

patients with symptomatic cholelithiasis in the past 2 months

patients with history of another known primary malignancy with exception of non-melanoma skin cancer or carcinoma in situ of uterine cervix

patients with known history of hepatitis C or chronic active hepatitis B

patients with diagnosis of HIV.

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)